|
KMID : 0361120140280020087
|
|
Korean Journal of Transplantation
2014 Volume.28 No. 2 p.87 ~ p.90
|
|
|
Treatment of Refractory Antibody-mediated Rejection with Bortezomib in a Kidney Transplant Recipient: A Case Report
|
|
Lee Ji-Yeon
Yoo Jin-Young
Kwon Soon-Hyo
Jeon Jin-Seok
Noh Hyun-Jin
Han Dong-Cheol
Song Dan
Jin So-Young
|
|
|
Abstract
|
|
|
|
Antibody-mediated rejection (ABMR) is associated with poor renal allograft survival. It shows poor response to conventional treatment with plasmapheresis, rituximab, and intravenous immunoglobulin. Bortezomib, a proteasome inhibitor used for treatment of multiple myeloma, has recently been reported as a treatment alternative for recipient desensitization and ABMR. A 58-year-old man was diagnosed with mixed-type ABMR with donor specific antibodies and acute T cell-mediated rejection early after kidney transplantation. Conventional therapy was administered, including antithymocyte globulin, plasmapheresis, and rituximab; however, his condition was found to be refractory to these antihumoral therapies. Following administration of bortezomib, his serum creatinine level returned to baseline with stable graft function. His serum creatinine level remains stable at 1.3 mg/dL at 10 months posttransplantation. Bortezomib is effective for treatment of refractory ABMR following kidney transplantation.
|
|
|
KEYWORD
|
|
|
Proteasome inhibitors, Antibody-mediated rejection, Kidney transplantation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|